摘要
目的通过联合检测血清DNA中p16、MGMT基因的异常甲基化以及血清细胞角蛋白19血清片段21-1(CYFRA21-1)的含量,以探讨联合检测在肺癌早期诊断中的临床意义。方法分离提取72例肺癌患者的外周血血清DNA,采用巢式甲基化特异性PCR方法检测p16、MGMT基因的甲基化状态,同时应用放射免疫法测定血清cYFRA21-1的含量,并以20例肺部良性疾病患者(BLD)和25例健康体检者作对照,分析两者联合应用的诊断价值。结果在52例肺癌患者血清中检测到p16基因的甲基化,阳性率为72.2%;47例肺癌患者血清中检测到MGMT基因的甲基化,阳性率为65.3%,而CYFRA21-1的阳性率为63.8%;平行联合检测时敏感性增至92.4%。BLD组p16、MGMT基因甲基化与CYFRA21-1阳性率分别为10.0%,5.0%和20.0%;健康对照者血清中p16、MGMT基因均无异常甲基化。结论联合检测血清p16、MGMT基因甲基化与CYFRA21-1含量可提高肺癌诊断的敏感性和特异性,对于肺癌的早期诊断具有重要意义。
Objective To evaluate the feasibility of combined detection of p16 and MGMT gene methylation and CYFRA21-1 in serum as an approach for diagnosis of lung cancer.Methods Serum DNA was extracted from 72 patients with lung cancer.The methylation of p16 and MGMT gene was detected by nested methylation specific polymerase chain reaction.Serum content of CYFRA21-1 was determined by radioimmunoassay.In addition,the results from 20 patients with benign lung disease and 25 healthy individuals were also analyzed as control.Results Aberrant promoter rmethylation of the p16 and MGMT gene was detected in 52 of 72（72.2%）,in 47 of 72（65.3%） of the serum samples.The positive rates of CYFRA21-1 were 63.4%（46/72）.Parallel combined test increasd the diagnostic sensitivity to 92.4%.The positive rates of pl6 and MGMT gene methylation and CYFRA21-1 of the group BLD were 10.0%,5.0% and 20.0%,respectively.No aberrant rmethylation of the p16 and MGMTgene was found in 25 healthy individuals.Conclusion Combined detection of p16 and MGMT gene methylation and CYFRA21-1 in serum could increase the sensitivity and specificity in diagnosing lung cancer.
出处
《中国公共卫生》
CAS
CSCD
北大核心
2008年第1期52-53,共2页
Chinese Journal of Public Health
基金
湖北省教育厅优秀中青年项目(Q200516001)
